Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scope Fluidics Spolka AkcyjnaWAR:SCP +2.19%42 Cash Ratio is 10.78 as of Mar. 2026, which is 16% above its 10-year median of 9.28. GuruFocus rates WAR:SCP with a GF Score™ of 42/100 and a GF Value™ of zł126.00 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 206 Medical Diagnostics & Research companies, Scope Fluidics Spolka Akcyjna ranks better than 97.09% on this metric.
Scope Fluidics Spolka Akcyjna has a Cash Ratio of 10.78. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Scope Fluidics Spolka Akcyjna's Cash Ratio or its related term are showing as below:
WAR:SCP'
s Cash Ratio Range Over the Past 10 Years
Min: 0.63 Med: 9.28 Max: 67
Current: 10.78
During the past 10 years, Scope Fluidics Spolka Akcyjna's highest Cash Ratio was 67.00. The lowest was 0.63. And the median was 9.28.
WAR:SCP's Cash Ratio is ranked better than 97.09% of 206
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.04
vs WAR:SCP: 10.78
Scope Fluidics Spolka Akcyjna (WAR:SCP) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Scope Fluidics Spolka Akcyjna Cash Ratio Related Terms
Scope Fluidics Spolka Akcyjna Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Scope Fluidics Spolka Akcyjna's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scope Fluidics Spolka Akcyjna Cash Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Scope Fluidics Spolka Akcyjna's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Scope Fluidics Spolka Akcyjna's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scope Fluidics Spolka Akcyjna (WAR:SCP) has a Cash Ratio of 10.78 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Scope Fluidics Spolka Akcyjna and its competitors. This is 16% above median its historical median of 9.28. Over the past decade, Scope Fluidics Spolka Akcyjna's Cash Ratio has ranged from 0.63 to 67.00. According to the industry distribution chart, Scope Fluidics Spolka Akcyjna ranks #6 out of 206 companies in the Medical Diagnostics & Research industry, placing it in the top 2.9%.
Is Scope Fluidics Spolka Akcyjna's Cash Ratio too high?
Scope Fluidics Spolka Akcyjna's current Cash Ratio of 10.78 is 16% above median its 10-year median of 9.28. Over the past 10 years, this metric has ranged from a low of 0.63 to a high of 67.00. The Medical Diagnostics & Research industry median Cash Ratio is 1.04. Scope Fluidics Spolka Akcyjna's value of 10.78 is 936.5% above this industry median. Based on the distribution chart, Scope Fluidics Spolka Akcyjna ranks #6 out of 206 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Scope Fluidics Spolka Akcyjna has a GF Score™ of 42/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Scope Fluidics Spolka Akcyjna's Cash Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Scope Fluidics Spolka Akcyjna ranks #6 out of 206 companies for Cash Ratio. This places Scope Fluidics Spolka Akcyjna in the top 3% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 1.04. Scope Fluidics Spolka Akcyjna's value of 10.78 is 936.5% above this benchmark. Historically, Scope Fluidics Spolka Akcyjna's own Cash Ratio has ranged from 0.63 to 67.00 over the past decade. While the company's 10-year median is 9.28 vs. the industry median of 1.04, Scope Fluidics Spolka Akcyjna has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Diagnostics & Research company?
The median Cash Ratio among Medical Diagnostics & Research companies is 1.04, based on 206 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scope Fluidics Spolka Akcyjna's current Cash Ratio of 10.78 is 936.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Scope Fluidics Spolka Akcyjna and its competitors. For the Medical Diagnostics & Research industry, the median Cash Ratio is 1.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scope Fluidics Spolka Akcyjna's current Cash Ratio is 10.78, which is 16% above median its own 10-year median of 9.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scope Fluidics Spolka Akcyjna stock overvalued right now?
Based on GuruFocus' analysis, Scope Fluidics Spolka Akcyjna (WAR:SCP) is currently considered Modestly Overvalued. The stock's GF Value™ is zł126.00, compared to a current price of zł140.20 — trading 11.3% above its estimated fair value. The current Cash Ratio is 10.78, which is 16% above median its 10-year median of 9.28 and 936.5% above the Medical Diagnostics & Research industry median of 1.04. Scope Fluidics Spolka Akcyjna's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Scope Fluidics Spolka Akcyjna (WAR:SCP), the current Cash Ratio is 10.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scope Fluidics Spolka Akcyjna (WAR:SCP) Overvalued in 2026?
Based on GuruFocus' analysis, Scope Fluidics Spolka Akcyjna stock appears to be overvalued.
The current stock price of zł140.20 is trading 11.3% above its estimated GF Value™ of zł126.00.
GuruFocus considers Scope Fluidics Spolka Akcyjna to be Modestly Overvalued.
Key valuation signals for WAR:SCP:
Cash Ratio: 10.78 (16% above median its 10-year median of 9.28)
GF Value™: zł126.00 vs. price of zł140.20 (11.3% above fair value)
Industry Position: 936.5% above the Medical Diagnostics & Research median (#6 of 206)
No single metric tells the full story. See the WAR:SCP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scope Fluidics Spolka Akcyjna focuses on global challenges in health to develop diagnostic and med tech solutions. The company combines the expertise in microfluidic technology with the awareness of the challenges in medical diagnostics. It provides prototyping support for diagnostic services.
42GF Score
Get the complete analysis for WAR:SCP
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SCP has been successfully added to your 
